ICVTS on-line discussion A. The safety of using millimolar doses of lidocaine as cardioplegia.
Fallouh
Hazem B
HB
Cardiac Surgery Department, St. Thomas' Hospital, London SE1 7EH, United Kingdom.
Chambers
David J
DJ
D000818:Animals; D002314:Cardioplegic Solutions / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D004489:Edema, Cardiac / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006324:Heart Arrest, Induced / Q000379:methods*; D006801:Humans; D008012:Lidocaine / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D017616:Magnesium Compounds / Q000494:pharmacology; D017680:Potassium Compounds / Q000494:pharmacology; D012107:Research Design; D026941:Sodium Channel Blockers / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects*
D002314:Cardioplegic Solutions; D017616:Magnesium Compounds; D017680:Potassium Compounds; D026941:Sodium Channel Blockers; D008012:Lidocaine